News

Analysis of 2 national surveys suggest a more than two-fold greater likelihood of depressed Americans endorsing a false fact about COVID-19 vaccines than others.

Despite the assumption of vaccine hesitancy among Black people in the US, the present study found rapid reductions in COVID-19 vaccine hesitancy among Black individuals in the US.

Bowel wall thickness and hyperemia in the neo-terminal ileum and bowel wall hyperemia at the ileocolic anastomosis were the only IUS parameters linked to endoscopic recurrence.

Balloon dilation is considered the gold standard in treating the complications associated with Crohn’s disease.

The therapeutic met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis with polyneuropathy, which included statistically significant improvements in neuropathy, and quality of life.

More than 70% of both groups met the primary efficacy outcomes.

The biggest theme identified was patients seeking peer-support and information about CPF symptoms, treatments, diet, experimental therapies, natural remedies, and patients’ apprehension regarding treatments.

Anti-TNF agents often cause various side effects, including inflammation.

Children of mothers with IBD are also more likely to be underdeveloped in height and weight compared to the control group.

While Omicron cases surge, Valentina, Baez-Sosa, MD, speaks on the national blood shortage and the risk it poses to patients with sickle cell disease in particular.

After its approval by the FDA, no new safety findings were reported on weekly dosing of the biologic.

The prevalence of AHT decreased by 6.7% each year during the study period, but the number of patients with AHT who died remained stable.

New data suggest hospitalized patients experience little difference in all-cause outcomes dependent on the busyness of their attending hospitalist.

Maureen Achebe goes into detail about the open label extension of the HOPE trial that evaluated to use of Voxelotor in patients with sickle cell disease and anemia.

Patients with asthma were at increased risk of hospitalization and ICU admission or death, prompting investigators to suggest these patients be considered a priority group for booster COVID-19 vaccines.

Dr. Ivy speaks on promising new therapies and training for sickle cell management during the first blood shortage in the United States in 10 years.

As the year begins, Edward Ivy addresses what's currently happening in the field of sickle cell disease from the impact of the blood shortage to exciting new therapies.

Only 12% of SER-109 treated patients had a recurrence, compared to 40% of the placebo group.

The endomina system can be affixed to various testing standard endoscopies for a bendable therapeutic channel.

Investigators note that validation of these biomarkers would require multi-center and independent validation of the current findings.

Data show the change in CHD prevalence from 2011 - 2018 (6.2% to 6.0%) was statistically insignificant.

Alloimmunization is more prevalent among patients with sickle cell disease than previous literature states. Baez-Sosa discusses her study and treatment practices.

Julia Haas, PhD, discusses her team's recent findings that one-third of patients in COVID-19 vaccine trials reported side effects after receiving a placebo dose.

Despite attempts climbing since 2008, investigators have observed no significant change in suicidal adults seeking care.

There are currently no approved systemic treatments for prurigo nodularis, but patients treated with dupilumab experienced significantly greater improvements in measures of overall health-related quality of life, skin pain, and symptoms of anxiety and depression.

Investigators observed that many patients with psoriasis are not actively seeing a primary care physician and would welcome management of their cardiovascular risk factors.

There are several barriers that prevent better HCV care, including availability and access to diagnostic and monitoring tests and the requirement for frequent medical visits during treatment.

Data show among patients with focal FDG uptake, PET/MRI and inflammatory blood markers resolved at follow-up performed at a mean of 52 days after baseline.